

## **USCAP 2017 - PSC Companion Meeting**

*Summary paper published in JASC and Acta Cytologica:*

### **The Bethesda System for Reporting Thyroid Cytopathology : Proposed Modifications and Updates for the Second Edition from an International Panel**

Marc Puzstaszeri<sup>1</sup>, Esther Diana Rossi<sup>2</sup>, Manon Auger<sup>3</sup>, Zubair Baloch<sup>4</sup>, Justin Bishop<sup>5</sup>,  
Massimo Bongiovanni<sup>6</sup>, Ashish Chandra<sup>7</sup>, Beatrix Cochand-Priollet<sup>8</sup>, Guido Fadda<sup>2</sup>,  
Mitsuyoshi Hirokawa<sup>9</sup>, SoonWong Hong<sup>10</sup>, Kennichi Kakudo<sup>11</sup>, Jeffrey F Krane<sup>12</sup>, Ritu  
Nayar<sup>13</sup>, Sareh Parangi<sup>14</sup>, Fernando Schmitt<sup>15</sup>, William C Faquin<sup>16</sup>.

<sup>1</sup> Department of Pathology, Geneva University Hospitals, Geneva, Switzerland.

<sup>2</sup> Division of Anatomic Pathology and Histology, Agostino Gemelli School of Medicine, Università Cattolica del Sacro Cuore, Rome, Italy.

<sup>3</sup> Department of Pathology, McGill University and McGill University Health Center, Montreal, Quebec, Canada.

<sup>4</sup> Department of Pathology and Laboratory Medicine, Hospital of the University of Pennsylvania, Perelman School of Medicine, Philadelphia, Pennsylvania, USA.

<sup>5</sup> Department of Pathology, Johns Hopkins School of Medicine, Baltimore, Maryland, USA.

<sup>6</sup> Institute of Pathology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland.

<sup>7</sup> Department of Cellular Pathology, Guy's & St Thomas' NHS Foundation Trust, London, United Kingdom.

<sup>8</sup> Department of Pathology, Cochin Hospital, Paris, France.

<sup>9</sup> Department of Diagnostic Pathology, Kuma Hospital, Kobe, Japan.

<sup>10</sup> Department of Pathology, Gang Nam Severance Hospital, Yonsei University, Seoul, South Korea.

<sup>11</sup> Department of Pathology, Nara Hospital, Kinki University Faculty of Medicine, Nara, Japan.

<sup>12</sup> Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA.

<sup>13</sup> Department of Pathology, Feinberg School of Medicine, Northwestern University and Northwestern Medicine, Chicago, Illinois, USA.

<sup>14</sup> Department of Surgery, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.

<sup>15</sup> Department of Medicine, Laboratoire National de Santé, Dudelange, Luxembourg.

<sup>16</sup> Department of Pathology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.

## **References**

- 1) Ali SZ, Cibas ES. The Bethesda system for reporting thyroid cytopathology. Definitions, criteria and explanatory notes. New York: Springer, 2010.
- 2) Bongiovanni M, Spitale A, Faquin WC, Mazzucchelli L, Baloch ZW. The Bethesda System for Reporting Thyroid Cytopathology: a meta-analysis. *Acta Cytol.* 2012;56:333-339.
- 3) Sheffield BS, Masoudi H, Walker B, Wiseman SM. Preoperative diagnosis of thyroid nodules using the Bethesda System for Reporting Thyroid Cytopathology: a comprehensive review and meta-analysis. *Expert Rev. Endocrinol. Metab.* 2014;9:97–110.
- 4) Haugen BR, Alexander E, Bible KC, et al. American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer. *Thyroid.* 2016;26:1-133.
- 5) Nikiforov YE, Seethala RR, Tallini G, et al. Nomenclature Revision for Encapsulated Follicular Variant of Papillary Thyroid Carcinoma: A Paradigm Shift to Reduce Overtreatment of Indolent Tumors. *JAMA Oncol.* 2016 Apr 14. [Epub ahead of print]
- 6) Baloch ZW, Seethala RR, Faquin WC, Papotti MG, Basolo F, Fadda G, Randolph GW, Hodak SP, Nikiforov YE, Mandel SJ. Noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP): A changing paradigm in thyroid surgical pathology and implications for thyroid cytopathology. *Cancer Cytopathol.* 2016 May 20. [Epub ahead of print]

- 7) Iskandar ME, Bonomo G, Avadhani V, Persky M, Lucido D, Wang B, Marti JL. Evidence for overestimation of the prevalence of malignancy in indeterminate thyroid nodules classified as Bethesda category III. *Surgery*. 2015;157:510-517.
- 8) Strickland KC, Howitt BE, Marqusee E, Alexander EK, Cibas ES, Krane JF, Barletta JA. The Impact of Noninvasive Follicular Variant of Papillary Thyroid Carcinoma on Rates of Malignancy for Fine-Needle Aspiration Diagnostic Categories. *Thyroid*. 2015;25:987-992.
- 9) Faquin WC, Wong LQ, Afrogheh AH, Ali SZ, Bishop JA, Bongiovanni M, Pusztaszeri MP, VandenBussche CJ, Gourmaud J, Vaickus LJ, Baloch ZW. Impact of reclassifying noninvasive follicular variant of papillary thyroid carcinoma on the risk of malignancy in The Bethesda System for Reporting Thyroid Cytopathology. *Cancer Cytopathol*. 2016;124:181-187.
- 10) Howitt BE, Chang S, Eszlinger M, Paschke R, Drage MG, Krane JF, Barletta JA. Fine-needle aspiration diagnoses of noninvasive follicular variant of papillary thyroid carcinoma. *Am J Clin Pathol*. 2015;144:850-857.
- 11) Maletta F, Massa F, Torregrossa L, Duregon E, Casadei GP, Basolo F, Tallini G, Volante M, Nikiforov YE, Papotti M. Cytological features of "non-invasive follicular thyroid neoplasm with papillary-like nuclear features" and their correlation with tumor histology. *Hum Pathol*. 2016 Apr 13. [Epub ahead of print]
- 12) Strickland KC, Vivero M, Jo VY, Lowe A, Hollowell M, Qian X, Wieczorek T, French CA, Teot LA, Eszlinger M, Paschke R, Sadow PM, Cibas E, Barletta JA, Krane JF. The Cytologic Diagnosis of Non-Invasive Follicular Variant of Papillary Thyroid Carcinoma: A Prospective Analysis. *Mod Pathol Suppl* 2016;29:117A-118A.
- 13) Nikiforov YE, Ohori P, Hodack SP, et al. Impact of mutational testing on the diagnosis and management of patients with cytologically indeterminate thyroid nodules: a prospective analysis of 1056 FNA samples. *J Clin Endocrinol Metabol*. 2011;96:3390-3397.

- 14) Nikiforova MN, Wald AI, Roy S, et al. Targeted next-generation sequencing panel (ThyroSeq) for detection of mutations in thyroid cancer J. Clin Endocrinol Metab. 2013;98:E1852-60.
- 15) Nikiforov YE, Carty SE, Chiosea SI, et al. Highly accurate diagnosis of cancer in thyroid nodules with molecular tests guide extent of thyroid surgery 767 follicular neoplasm/suspicious for a follicular neoplasm cytology by ThyroSeq v2 next-generation sequencing assay. Cancer. 2014;120:3627–3634.
- 16) Nikiforov YE, Carry SE, Chiosea SI, et al. Impact of the multigene ThyroSeq next generation sequencing assay on cancer diagnosis in thyroid nodules with atypia of undetermined significance/follicular lesion of undetermined significance cytology. Thyroid 2015;120:3627-3634.
- 17) Alexander EK, Kennedy GC, Baloch ZW, et al. Preoperative diagnosis of benign thyroid nodules with indeterminate cytology. N Engl J Med. 2012; 367:705-715.
- 18) Krane JF, Vanderlaan PA, Faquin WC, Renshaw AA. The atypia of undetermined significance/follicular lesion of undetermined significance:malignant ratio: a proposed performance measure for reporting in The Bethesda System for thyroid cytopathology. Cancer Cytopathol. 2012;120:111-116.
- 19) Singh RS, Wang HH. Timing of repeat thyroid fine-needle aspiration in the management of thyroid nodules. Acta Cytol. 2011;55:544-548.
- 20) Lubitz CC, Nagarkatti SS, Faquin WC, Samir AE, Hassan MC, Barbesino G, Ross DS, Randolph GW, Gaz RD, Stephen AE, Hodin RA, Daniels GH, Parangi S. Diagnostic yield of nondiagnostic thyroid nodules is not altered by timing of repeat biopsy. Thyroid 2012;22:590-594.
- 21) Tee YY, Lowe AJ, Brand CA, Judson RT. Fine-needle aspiration may miss a third of all malignancy in palpable thyroid nodules: a comprehensive literature review. Ann Surg. 2007;246:714-720.

- 22) Nou E, Kwong N, Alexander LK, Cibas ES, Marqusee E, Alexander EK. Determination of the optimal time interval for repeat evaluation after a benign thyroid nodule aspiration. *J Clin Endocrinol Metab.* 2014;99:510-516.
- 23) Nishino M, Wang HH. Should the thyroid AUS/FLUS category be further stratified by malignancy risk? *Cancer Cytopathol* 2014;122:481-483.
- 24) VanderLaan PA, Marqusee E, Krane JF. Usefulness of diagnostic qualifiers for thyroid fine-needle aspirations with atypia of undetermined significance. *Am J Clin Pathol.* 2011;136:572-577.
- 25) Renshaw AA. Subclassification of atypical cells of undetermined significance in direct smears of fine-needle aspirations of the thyroid: distinct patterns and associated risk of malignancy. *Cancer Cytopathol.* 2011;119:322-327.
- 26) Chen JC, Pace SC, Khiyami A, McHenry CR. Should atypia of undetermined significance be subclassified to better estimate risk of thyroid cancer?. *American Journal of Surgery.* 207:331-336.
- 27) Wu HH, Inman A, Cramer HM. Subclassification of "atypia of undetermined significance" in thyroid fine-needle aspirates. *Diagnostic Cytopathology.* 2014;42:23-29.
- 28) Luu MH, Fischer AH, Stockl TJ, Pisharodi L, Owens CL. Atypical follicular cells with equivocal features of papillary thyroid carcinoma is not a low-risk cytologic diagnosis. *Acta Cytol.* 2011; 55:526-530.
- 29) Yang GC, Schreiner AM, Sun W. Can abundant colloid exclude oncocyctic (Hürthle cell) carcinoma in thyroid fine needle aspiration? Cytohistological correlation of 127 oncocyctic (Hürthle cell) lesions. *Cytopathology.* 2013;24:185-193
- 30) Harrell RM, Bimston DN. Surgical utility of Afirma: effects of high cancer prevalence and oncocyctic cell types in patients with indeterminate thyroid cytology. *Endocr Pract.* 2014;20:364-369.

- 31) Lastra RR, Pramick MR, Crammer CJ, LiVolsi VA, Baloch ZW. Implications of a suspicious Afirma test result in thyroid fine-needle aspiration cytology: an institutional experience. *Cancer Cytopathol.* 2014;122:737-744.
- 32) McIver B, Castro MR, Morris JC, Bernet V, Smallridge R, Henry M, Kosok L, Reddi H. An independent study of a gene expression classifier (Afirma) in the evaluation of cytologically indeterminate thyroid nodules. *J Clin Endocrinol Metab.* 2014;99:4069-4077.
- 33) Brauner E, Holmes BJ, Krane JF, Nishino M, Zurakowski D, Hennessey JV, Faquin WC, Parangi S. Performance of the Afirma Gene Expression Classifier in Hürthle Cell Thyroid Nodules Differs from Other Indeterminate Thyroid Nodules. *Thyroid.* 2015;25:789-796.
- 34) Suzuki A, Hirokawa M, Higuchi M, Yamao N, Kuma S, Nakamura H, Amino N, Miyauchi A. Cytological characteristics of papillary thyroid carcinoma on LBC specimens, compared with conventional specimens. *Diagn Cytopathol.* 2015;43:108-113.
- 35) Fischer AH, Clayton AC, Bentz JS, Wasserman PG, Henry MR, Souers RJ, Moriarty AT. Performance differences between conventional smears and liquid-based preparations of thyroid fine-needle aspiration samples: analysis of 47,076 responses in the College of American Pathologists Interlaboratory Comparison Program in Non-Gynecologic Cytology. *Arch Pathol Lab Med.* 2013;137:26-31.
- 36) Cancer Genome Atlas Research Network. Integrated genomic characterization of papillary thyroid carcinoma. *Cell.* 2014;159:676-690.
- 37) Rivera M, Ricarte-Filho J, Knauf J, Shaha A, Tuttle M, Fagin JA, Ghossein RA. Molecular genotyping of papillary thyroid carcinoma follicular variant according to its histological subtypes (encapsulated vs infiltrative) reveals distinct BRAF and RAS mutation patterns. *Mod Pathol.* 2010;23:1191-1200.
- 38) Liu J, Singh B, Tallini G, Carlson DL, Katabi N, Shaha A, Tuttle RM, Ghossein RA. Follicular variant of papillary thyroid carcinoma: a clinicopathologic study of a problematic entity. *Cancer.* 2006 Sep 15;107:1255-1264.

- 39) Ganly I, Wang L, Tuttle RM, Katabi N, Ceballos GA, Harach HR, Ghossein R. Invasion rather than nuclear features correlates with outcome in encapsulated follicular tumors: further evidence for the reclassification of the encapsulated papillary thyroid carcinoma follicular variant. *Hum Pathol*. 2015;46:657-664.
- 40) Carney JA, Hirokawa M, Lloyd RV, Papotti M, Sebo TJ. Hyalinizing trabecular tumors of the thyroid gland are almost all benign. *Am J Surg Pathol*. 2008;32:1877-1889.
- 41) Wells SA Jr, Asa SL, Dralle H, et al. Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. *Thyroid*. 2015;25:567-610.
- 42) Trimboli P, Guidobaldi L, Bongiovanni M, Crescenzi A, Alevizaki M, Giovanella L. Use of fine-needle aspirate calcitonin to detect medullary thyroid carcinoma: A systematic review. *Diagn Cytopathol*. 2015 Oct 19. [Epub ahead of print]
- 43) Puztaszeri MP, Bongiovanni M, Faquin WC. Update on the cytologic and molecular features of medullary thyroid carcinoma. *Adv Anat Pathol*. 2014;21:26-35.
- 44) Kaushal S, Iyer VK, Mathur SR, Ray R. Fine needle aspiration cytology of medullary carcinoma of the thyroid with a focus on rare variants: a review of 78 cases. *Cytopathology*. 2011;22:95-105.
- 45) Kane SV, Sharma TP. Cytologic diagnostic approach to poorly differentiated thyroid carcinoma: a single-institution study. *Cancer Cytopathol*. 2015;123:82-91.
- 46) La Bryer L, Sawh R, McLaurin C, Scofield RH. Calcitonin-Secreting Neuroendocrine Carcinoma of Larynx with Metastasis to Thyroid. *Case Reports in Endocrinology* 2015;2015:606389.
- 47) Bai S, Baloch ZW, Samulski TD, Montone KT, LiVolsi VA. Poorly differentiated oncocyctic (hürthle cell) follicular carcinoma: an institutional experience. *Endocr Pathol*. 2015;26:164-169.

- 48) Bellevicine C, Iaccarino A, Malapelle U, Sasso FC, Biondi B, Troncone G. PAX8 is expressed in anaplastic thyroid carcinoma diagnosed by fine-needle aspiration: a study of three cases with histological correlates. *Eur J Endocrinol.* 2013;169:307-311.
- 49) Bishop JA, Sharma R, Westra WH. PAX8 immunostaining of anaplastic thyroid carcinoma: a reliable means of discerning thyroid origin for undifferentiated tumors of the head and neck. *Hum Pathol.* 2011;42:1873-1877.
- 50) Rivera M, Sang C, Gerhard R, Ghossein R, Lin O. Anaplastic thyroid carcinoma: morphologic findings and PAX-8 expression in cytology specimens. *Acta Cytol.* 2010;54:668-672.
- 51) Pusztaszeri M, Wang H, Cibas ES, Powers CN, Bongiovanni M, Ali S, Khurana KK, Michaels PJ, Faquin WC. Fine-needle aspiration biopsy of secondary neoplasms of the thyroid gland: a multi-institutional study of 62 cases. *Cancer Cytopathol.* 2015;123:19-29.
- 52) Rossi ED, Martini M, Straccia P, Gerhard R, Evangelista A, Pontecorvi A, Fadda G, Maria Larocca L, Schmitt F. Is thyroid gland only a "land" for primary malignancies? role of morphology and immunocytochemistry. *Diagn Cytopathol.* 2015;43:374-380.